A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

MLA

Mussini, Cristina, et al. “A Prospective Randomized Trial on Abacavir/Lamivudine plus Darunavir/Ritonavir or Raltegravir in HIV-Positive Drug-Naïve Patients with CD4<200 Cells/UL (the PRADAR Study).” PLoS ONE, vol. 14, no. 9, Sept. 2019, pp. 1–11. EBSCOhost, https://doi.org/10.1371/journal.pone.0222650.

APA

Mussini, C., Roncaglia, E., Borghi, V., Rusconi, S., Nozza, S., Cattelan, A. M., Segala, D., Bonfanti, P., Di Biagio, A., Barchi, E., Focà, E., Degli Antoni, A., Bonora, S., Francisci, D., Limonta, S., Antinori, A., D, E. G., & Maggiolo, F. (2019). A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study). PLoS ONE, 14(9), 1–11. https://doi.org/10.1371/journal.pone.0222650

Chicago

Mussini, Cristina, Enrica Roncaglia, Vanni Borghi, Stefano Rusconi, Silvia Nozza, Anna Maria Cattelan, Daniela Segala, et al. 2019. “A Prospective Randomized Trial on Abacavir/Lamivudine plus Darunavir/Ritonavir or Raltegravir in HIV-Positive Drug-Naïve Patients with CD4<200 Cells/UL (the PRADAR Study).” PLoS ONE 14 (9): 1–11. doi:10.1371/journal.pone.0222650.